Victoza®

DRUG4 trials

Sponsors

ikfe-CRO GmbH, PhaseBio Pharmaceuticals Inc., University of Oulu

Conditions

Diabetes Mellitus, Type 2Type 1 DiabetesType 2 Diabetes Mellitus

Phase 2

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

CompletedNCT01658501

PhaseBio Pharmaceuticals Inc.Type 2 Diabetes Mellitus

Start: 2012-07-31End: 2013-07-31Updated: 2015-12-07

Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

University of OuluType 1 Diabetes

Start: 2015-12-31End: 2024-06-30Target: 42Updated: 2022-01-25

Incretin-based Therapy in Late Preclinical Type 1 Diabetes

CompletedNCT02898506

University of OuluType 1 Diabetes

Start: 2016-03-31End: 2021-06-30Updated: 2022-01-25

Phase 4

Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

CompletedNCT01208012

ikfe-CRO GmbHDiabetes Mellitus, Type 2

Start: 2010-04-30End: 2010-11-30Updated: 2011-03-15

Related Papers

<scp>INnoVative</scp> trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 <scp>DIAbetes</scp> in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (<scp>INVESTDIA</scp>)

Diabetic Medicine2022-07-072 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01